NLRP3 and COVID-19: The SARS-CoV-2 virus activates NLRP3 (14–18), and this inflammasome has been implicated in the production of pro-inflammatory cytokines in severe cases of COVID-19 and is thus directly associated with the severity of ARDS (15, 19, 20).